Reviewer's report
Title:Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis
in a thioacetamide-induced cirrhotic rat model
Version:3Date:10 June 2014
Reviewer: Jonel Trebicka
Reviewer's report:
The authors have analyzed the role of BM-MSC in the regression of fibrosis.
They injected human BM-MSC directly intrahepatically and could show a
decrease in fibrosis after two injections.
major comments:
1. the topic is not novel and the methods used neither. However, it confirms that
BM-MSC might play a role in the therapy of fibrosis. Indeed several points need
to be adressed before publication. On my opinion more efforts should be
invested in the analysis of fibroslysis. what happens to the different MMPs and
TIMPs, etc.
2. Teh model of TAA in rats with i.p. injections sounds difficult, however the
authros show severe fibrosis. do the rats develop ascites?
3. what did the control group receive? the control groups should also receive a
cellular suspension
4. did the authros used analog liver segments for hydroxy prolin? which
segemnts, where teh injection is? this must be clear
5. where did the BM-MSC end up? teh authros should stain the livers for human
antigens and analyze their location
6. what happens to the laboratory tests and blood tests? did the authors noticed
more inflammatory inflitrates in teh liver?
minor comments:
1. the basal data as liver weight, body weight, spleen weight etc must be shown
2. the laboratory data (liver and blood) should be shown
3. the Spleen and other orgens should be analyze to see whtehr the cells migrate
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no competing interest
Reviewer's report
Title:Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis
in a thioacetamide-induced cirrhotic rat model
Version:3Date:10 June 2014
Reviewer: Jonel Trebicka
Reviewer's report:
The authors have analyzed the role of BM-MSC in the regression of fibrosis.
They injected human BM-MSC directly intrahepatically and could show a
decrease in fibrosis after two injections.
major comments:
1. the topic is not novel and the methods used neither. However, it confirms that
BM-MSC might play a role in the therapy of fibrosis. Indeed several points need
to be adressed before publication. On my opinion more efforts should be
invested in the analysis of fibroslysis. what happens to the different MMPs and
TIMPs, etc.
2. Teh model of TAA in rats with i.p. injections sounds difficult, however the
authros show severe fibrosis. do the rats develop ascites?
3. what did the control group receive? the control groups should also receive a
cellular suspension
4. did the authros used analog liver segments for hydroxy prolin? which
segemnts, where teh injection is? this must be clear
5. where did the BM-MSC end up? teh authros should stain the livers for human
antigens and analyze their location
6. what happens to the laboratory tests and blood tests? did the authors noticed
more inflammatory inflitrates in teh liver?
minor comments:
1. the basal data as liver weight, body weight, spleen weight etc must be shown
2. the laboratory data (liver and blood) should be shown
3. the Spleen and other orgens should be analyze to see whtehr the cells migrate
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no competing interest
Please review this paper.
user
Reviewer's report
Title:Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis
in a thioacetamide-induced cirrhotic rat model
Version:3Date:10 June 2014
Reviewer: Jonel Trebicka
Reviewer's report:
The authors have analyzed the role of BM-MSC in the regression of fibrosis.
They injected human BM-MSC directly intrahepatically and could show a
decrease in fibrosis after two injections.
major comments:
1. the topic is not novel and the methods used neither. However, it confirms that
BM-MSC might play a role in the therapy of fibrosis. Indeed several points need
to be adressed before publication. On my opinion more efforts should be
invested in the analysis of fibroslysis. what happens to the different MMPs and
TIMPs, etc.
2. Teh model of TAA in rats with i.p. injections sounds difficult, however the
authros show severe fibrosis. do the rats develop ascites?
3. what did the control group receive? the control groups should also receive a
cellular suspension
4. did the authros used analog liver segments for hydroxy prolin? which
segemnts, where teh injection is? this must be clear
5. where did the BM-MSC end up? teh authros should stain the livers for human
antigens and analyze their location
6. what happens to the laboratory tests and blood tests? did the authors noticed
more inflammatory inflitrates in teh liver?
minor comments:
1. the basal data as liver weight, body weight, spleen weight etc must be shown
2. the laboratory data (liver and blood) should be shown
3. the Spleen and other orgens should be analyze to see whtehr the cells migrate
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
no competing interest
assistant